Effects of coenzyme Q10 supplementation on matrix metalloproteinases and DAS-28 in patients with rheumatoid arthritis: a randomized, double-blind, placebo-controlled clinical trial
This study aimed to assess the effect of CoQ10 supplementation on serum matrix metalloproteinases (MMPs) and clinical parameters in rheumatoid arthritis (RA) patients.
In this randomized, double-blind, placebo-controlled trial, 54 RA patients who fulfilled the eligibility criteria (18–56 years, diagnosed at least 6 months ago, with DAS-28 > 3.2) were randomly assigned into two groups to receive 100 mg/day CoQ10 (n = 27) or placebo (n = 27) for 2 months. Serum MMP-1 and MMP-3 levels and clinical status using disease activity score in 28 joints (DAS-28) were assessed before and after supplementation. Data were analyzed using χ2, independent sample t test, paired t test, Wilcoxon, Mann-Whitney, and analysis of covariance.
A significant reduction was observed in both CoQ10 and placebo groups in the medians of serum MMP-1 (0.2 to 0.16, P < 0.001), (0.18 to 0.15, P = 0.001); swollen joint count (2 to 0, P < 0.001), (2 to 0, P = 0.009); and the means of DAS-28 (5.01 ± 1.21 to 2.34 ± 0.68, P < 0.001), (4.88 ± 0.96 to 4.04 ± 1.36, P = 0.009) respectively. Serum MMP-3 level increased significantly in placebo group (2.26 to 2.57, P = 0.020), and the MMP-3 changes between groups were significant (P = 0.027). Furthermore, significant reductions were only observed in ESR, pain score, and tender joint count in CoQ10 group compared with baseline (P = 0.001, P < 0.001, and P < 0.001, respectively). Significant differences were observed between two groups in DAS-28, pain score, and swollen and tender joint count after the intervention (P < 0.001, P < 0.001, and P = 0.012 and P < 0.001, respectively).
• CoQ10 supplementation in RA patients attenuated serum MMP-3 level.
• CoQ10 supplementation in RA patients improved clinical outcomes and ameliorated disease severity.
• CoQ10 may provide a new complementary approach for patients with RA.
KeywordsClinical parameters Clinical trial Coenzyme Q10 Matrix metalloproteinases Rheumatoid arthritis
Analysis of covariance
Body mass index
Disease activity score-28 joints
Disease-modifying anti-rheumatic drugs
Erythrocyte sedimentation rate
Fibromyalgia Impact Questionnaire
High-sensitivity C-reactive protein
Tumor necrosis factor-alpha
visual analogue scale
We thank all patients for their participation in this study.
The research project had a grant from Research Vice Chancellor of Tabriz University of Medical Sciences. The authors thank the Research Vice Chancellor of Tabriz University of Medical Sciences for financial supports.
Compliance with ethical standards
- 1.Aletaha D, Neogi T, Silman A, Funovits J, Felson D, Bingham C, Birnbaum NS, Burmester GR, Bykerk VP, Cohen MD (2010) 2010 rheumatoid arthritis classification criteria: an American College of Rheumatology/European League against Rheumatism collaborative initiative. Arthritis Rheum 62:2569–2581CrossRefGoogle Scholar
- 6.Ainola M, Mandelin J, Liljeström MP, Li T, Hukkanen M, Konttinen Y (2005) Pannus invasion and cartilage degradation in rheumatoid arthritis: involvement of MMP-3 and interleukin-1b. Clin Exp Rheumatol 23:644–650Google Scholar
- 8.Mamehara A, Sugimoto T, Sugiyama D, Morinobu S, Tsuji G, Kawano S, Morinobu A, Kumagai S (2010) Serum matrix metalloproteinase-3 as predictor of joint destruction in rheumatoid arthritis, treated with non-biological disease modifying anti-rheumatic drugs. Kobe J Med Sci 56:E98–E107Google Scholar
- 9.Sekhon BS (2010) Matrix metalloproteinases an overview. Res Rep Biol 1:1–20Google Scholar
- 18.Bauerova K, Paulovicova E, Mihalova D, Drafi F, Strosova M, Mascia C, Biasi F, Rovensky J, Kucharska J, Gvozdjakova A, Ponist S (2010) Combined methotrexate and coenzyme Q10 therapy in adjuvant-induced arthritis evaluated using parameters of inflammation and oxidative stress. Acta Biochim Pol 57:347–354CrossRefGoogle Scholar
- 19.Gvozdjáková A, Kucharská J, Poništ S, Bauerová K (2007) Coenzyme Q10 supplementation in an experimental model of adjuvant arthritis. Fifth Conference of the International Coenzyme Q10 Association, Kobe, Japan Abstract book, JP-053:180–181Google Scholar
- 20.Spindler M, Beal MF, Henchcliffe C (2009) Coenzyme Q10 effects in neurodegenerative disease. Neuropsychiatr Dis Treat 5:597Google Scholar
- 24.Reneses S, Pestana L, Garcia A (2012) Comparison of the 1987 ACR criteria and the 2010 ACR/EULAR criteria in an inception cohort of patients with recent-onset inflammatory polyarthritis. Clin Exp Rheumatol 30:417–420Google Scholar
- 27.Hammond KA, Litchford MD (2012) Clinical: inflammation, physical, and functional assessment. In: Mahan LK, Escott-Stump S (eds) Krause’s food & nutrition therapy, 13th edn. Saunders, Philadelphia, pp 163–177Google Scholar
- 28.Vander Cruyssen B, Van Looy S, Wyns B, Westhovens R, Durez P, Van den Bosch F, Veys EM, Mielants H, Clerck LD, Peretz A, Malaise M, Verbruggen L, Vastesaeger N, Geldhof A, Boullart L, De Keyser F (2005) DAS28 best reflects the physician's clinical judgment of response to infliximab therapy in rheumatoid arthritis patients: validation of the DAS28 score in patients under infliximab treatment. Arthritis Res Ther 7:R1063–R1071CrossRefGoogle Scholar
- 29.Sokka T (2005) Assessment of pain in rheumatic diseases. Clin Exp Rheumatol 23:S77–S84Google Scholar
- 30.Hawker GA, Mian S, Kendzerska T, French M (2011) Measures of adult pain: visual analog scale for pain (vas pain), numeric rating scale for pain (nrs pain), mcgill pain questionnaire (mpq), short form mcgill pain questionnaire (sf mpq), chronic pain grade scale (cpgs), short form 36 bodily pain scale (sf 36 bps), and measure of intermittent and constant osteoarthritis pain (icoap). Arthritis Care Res 63:S240–SS52CrossRefGoogle Scholar
- 31.DAS 28 calculator V1.1-beta by Alfons and Michiel. Available online: http://www.umcn.nl.DAS28. Accessed on 5 March 2016
- 32.Nielung L, Christensen R, Danneskiold-Samsøe B, Bliddal H, Holm CC, Ellegaard K, Slott Jensen H, Bartels EM (2015) Validity and agreement between the 28-joint disease activity score based on C-reactive protein and erythrocyte sedimentation rate in patients with rheumatoid arthritis. Arthritis 2015:1–6CrossRefGoogle Scholar
- 33.Fransen J, Stucki G, Van Riel PL (2003) Rheumatoid arthritis measures: disease activity score (DAS), disease activity score 28 (DAS28), rapid assessment of disease activity in rheumatology (RADAR), and rheumatoid arthritis disease activity index (RADAI). Arthritis Care Res 49:S214–SS24CrossRefGoogle Scholar
- 38.Sanoobar M, Eghtesadi S, Azimi A, Khalili M, Khodadadi B, Jazayeri S, Gohari MR, Aryaeian N (2014) Coenzyme Q10 supplementation ameliorates inflammatory markers in patients with multiple sclerosis: a double blind, placebo, controlled randomized clinical trial. Nutr Neurosci 18:169–176CrossRefGoogle Scholar